Patients with newly diagnosed giant cell arteritis (GCA) experience significant delays in accessing subcutaneous tocilizumab (TCZ), with an average wait of 43 days from medication request to ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for the condition since tocilizumab in ...

GCA is an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium arteries. If left untreated, the disease can lead to ...

AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell arteritis (GCA), or temporal arteritis, an autoimmune disease of medium ...

Also referred to as temporal arteritis, GCA is stated to be an autoimmune condition affecting medium and large-sized arteries, marked by the granulomatous inflammation of the three-layered vessel wall ...

We report for the first time a case of Erdheim-Chester disease with histologic evidence of temporal artery inflammation in a patient who had symptoms of giant cell arteritis. 2. Case Report Evaluation ...

Also known as temporal arteritis, giant cell arteritis (GCA) is inflammation of the lining of the arteries that run along the temple. GCA usually creates a headache that causes constant, throbbing ...

GCA, also known as temporal arteritis, is the most prevalent form of vasculitis in Western countries, affecting adults’ cranial arteries and potentially leading to serious health complications, ...

GCA is an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium arteries. If left untreated, the disease can lead to ...

GCA is an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium arteries. The European Commission had recently granted ...